1st Symposium on Iron Metabolism and Cancer
24 October 2023 | i3S, Porto
The 1st Symposium on Iron Metabolism and Cancer will be held on the 24th of October 2023, in Porto.
This one-day symposium is a meeting where top scientists working in iron metabolism and cancer come together to discuss the advances in basic and clinical research on iron-mediated phenomena in cancer, the contribute of ferroptosis, and potential breakthroughs in iron-cancer axis at the therapeutic level.
Target audience: All scientific community.
The meeting will be held at i3S – Instituto de Investigação e Inovação em Saúde.
Rua Alfredo Allen, 208; 4200-135 Porto, Portugal
Tel: +351 226 074 900 | Site: http://www.i3s.up.pt/ | E-mail: email@example.com
GPS coordinates: 41º 10’ 30.008’’ N, 8º 36’ 12.488’’ W.
Tânia Cruz, PhD
Diogo Estêvão, PhD student
Miguel da Cruz Ribeiro, MSc
Maria José Oliveira, PhD
09.00-09.30 Registration and Welcoming
Chairs: Tânia Cruz, Maria José Oliveira
09.30-10.15 | Iron in leukemia: friend or foe?
Delfim Duarte, i3S, Instituto de Investigação e Inovação em Saúde, Portugal
10.15-10.30 | Iron overload induces dysplastic erythropoiesis and features of myelodysplasia in Nrf2-deficient mice
Tiago Duarte, i3S, Instituto de Investigação e Inovação em Saúde, Portugal
10.30-10.45 | Apotransferrin in combination with induction chemotherapy has an anti-leukemic effect in an acute myeloid leukemia mouse model
Marta Lopes, i3S, Instituto de Investigação e Inovação em Saúde, Portugal
10.45-11.30 Coffee Break & Poster Session and evaluation
Chairs: Diogo Estevão, Miguel Ribeiro
11.30-12.00 | SPEED TALK SESSION I
#1 Lidia Rocha | Failure of bone marrow erythropoiesis in acute myeloid leukemia is driven by loss of erythroblastic islands
#5 Joana Reis | The protective role of cell extrinsic Nrf2 in hematopoietic stem cell transplantation with iron overload
#7 Liliana Arede | In vitro clonogenic potential of PBMCs from Hereditary Hemochromatosis patients
#3 Oscar Fonseca | The shift in iron metabolism: a new anti-inflammatory strategy?
Chairs: Maria José Oliveira, Diogo Estêvão
12-12.45 | Ferroptosis in cancer cells and immunomodulation
Peter Vandenabelee, Ghent University's Faculty of Sciences, Belgium
13.00-14.00 Lunch time at i3S & Poster Session
Chairs: Tânia Cruz, Miguel Ribeiro
14.00-14.45 | Iron-dependent pharmacology from malaria to cancer
Diogo Magalhães e Silva, iMed.UL, Portugal
14.45-15.00 | Exploiting Iron Metabolism to Overcome Chemoresistance in Neuroblastoma
Adriana Manas, Lund University, Sweden
Chairs: Tiago Duarte, Diogo Magalhães e Silva (to be confirmed)
15.00-15.30 | SPEED TALKS SESSION II
#6 Nicole Viveiros | The role of the heme-exporter FLVCR1 in hepatocellular carcinoma
#11 Diogo Estêvão | Radiotherapy and iron metabolism in rectal cancer: fueling or killing cancer cells?
#8 Ângela Costa | SLC11A2 (DMT1) expression is downregulated by macrophagic infiltration at right colon tumors
#10 Carla Vitorino | Enhanced glioblastoma treatment with chemodynamic-hybrid nanoparticles
15.30-16.30 Coffee Break & Poster Session and evaluation
Chair: Graça Porto, Maria José Oliveira
16:30-17.15 | Reprograming the tumor microenvironment with iron: Combination therapy of crizotinib and super-paramagnetic iron oxide nanoparticles reduces lung cancer relapse
Martina Muckenthaler, University of Heidelberg, Germany
Chair: Organizing committee
17.15-17.45 | Round table: What´s the next big’Irony?
All the invited speakers.
17.45-18.00 Closing Session and Awards
Peter Vandenabeele is a Senior Full Professor at Ghent University's Faculty of Sciences, head of the VIB Inflammation Research Center's Molecular Signaling and Cell Death Unit, and leader of the Cell Death and Inflammation research group. Professor Peter is regarded as one of the pioneers in the field of cell death research namely, of Ferroptosis, a rather recent discovered cell death mechanism that is characterized by iron accumulation and the buildup of lipid peroxides inside cells. He disputed a number of established theories on cell death and characterized its different modalities by distinct enzymatic pathways, kinase roles as well as the release of Damage-Associated Molecular Patterns (DAMPs).
Professor Peter and his team also developed a large cellular screening platform to assist in the identification of novel targets in signalling of cell death modalities in which customized functional classes of sh/siRNAs libraries and known clinical drugs or novel chemical compounds are screened. The hits are then further examined in cellular systems and in experimental disease models for their potential to modulate cell death pathways or to influence disease models.
Martina Muckenthaler is a group leader in the Molecular Medicine Partnership Unit (MMPU) between the University of Heidelberg and the European Molecular Biology Laboratory. She is also a professor of molecular medicine at the Department of pediatric hematology, oncology, and immunology at Ruprecht-Karls University in Heidelberg (EMBL).
Her research is mainly focused on hepcidin and ferroportin axis and their regulatory mechanisms, as well as the pathophysiological effects of iron overload and iron deficiency. Her team uses network-based analyses, as well as integration of transcriptome and proteome data, genome-wide screens, and disease models.
Importantly, Martina highly contributes to patient-oriented research aiming at continuously improving the diagnosis and treatment strategies of rare hematological diseases. Together with her colleagues from nationwide hospitals, they lead the registry studies for patients with rare anemias of the Society for Pediatric Oncology and Hematology.
Delfim Duarte is a physician-scientist, head of the Hematopoiesis and Microenvironments Group at the Institute for Innovation and Health i3s, Porto and medical doctor at the IPO-Porto Hematology Service. Understanding the relationships between malignant and non-malignant hematopoietic cells and their surrounding microenvironments is of primary interest to Delfim and his team.
His recent studies have demonstrated the systemic and local effects of iron metabolism dysregulation in acute myeloid leukemia, breaking the grounds to explore the influence of iron on liquid cancers.
Diogo Magalhães e Silva
Diogo Magalhães e Silva is currently a project leader of a CaixaResearch Validate grant with the main goal of exploring drug delivery systems for colorectal cancer. He is a former Fulbright fellow at University of California, San Francisco (UCSF) in Renslo Lab, passionate about science, innovation and entrepreneurship.
Diogo aims at developing solutions that can have an impact in Human Health, with research focus on the deregulation of iron metabolism in cancer to improve the selectivity of anti-cancer drugs. His work resulted in two patent applications and eight important publications on Drug Discovery and Development.
The call for abstracts will be open until the 8th of September (notification of acceptance until the 11th of September). The abstract will be evaluated and selected either for oral communication or poster communication.
Abstracts should be structured according to the following template:
Students – 45€
Others – 60€
Registration deadline: 13th September 2023 | Payment deadline: 18th September 2023
Nutrients (IF: 5.9, ISSN 2072-6643) is an on-line open access journal that was first published in 2009. Nutrients adheres to rigorous peer review and editorial processes and publishes only high-quality manuscripts that address important issues related to the impacts of nutrients on human health.
Events Management Unit | Rua Alfredo Allen 208 | 4200-135 Porto, Portugal
Email: firstname.lastname@example.org | Tel: +351 226 074 900